Sopharma

Founded in 1933 and headquartered in Sofia, Bulgaria, Sopharma AD is a publicly traded, revenue-generating pharmaceutical company focused on generic drugs. It has established a significant international footprint with a portfolio of nearly 530 products sold in over 80 countries and operates ten manufacturing plants across Bulgaria, Serbia, and Ukraine. The company is led by Executive Director Ognian Donev and is a benchmark for quality in the region, with a market capitalization of approximately €750 million on the Bulgarian Stock Exchange. Its business model is centered on the commercial production and sale of therapeutics, supported by contract manufacturing and development services for partners.

Vertically integrated manufacturing platform for generic pharmaceuticals and APIs, compliant with international GDP and GLP standards. Offers contract manufacturing and product development services.

Operates in the highly competitive global generic pharmaceuticals market, competing on price, quality, and reliability against other large generics manufacturers (e.g., Teva, Sandoz) and regional players. Its competitive advantage lies in its strong brand recognition in Eastern Europe, cost-effective manufacturing base, and broad portfolio.